Operator (Manufacturing)

Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands. We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients. If you are up to the challenge and would like to be part of our team, we are currently looking for an Operator.

As an Operator at Kiadis Pharma, you will:

  • Perform all required manufacturing process steps to ensure timely delivery of Kiadis products while securing Quality, Safety, Health and environment standards.
  • Independently perform manufacturing process steps.
  • Contribute to keeping Manufacturing documentation up-to-date.
  • Contribute to continuous improvement of the manufacturing department
  • Collaborate with PD to facilitate development and qualification of manufacturing steps.

The ideal candidate  

  • Holds a HBO degree in biotechnology or related field (or equivalent through experience).
  • Has at least two years of relevant working experience in a GMP environment.
  • Hands-on experience in writing GMP documentation
  • Fluent in Dutch and good command of the English language.

We offer

A challenging position in an innovative, fast growing, biotechnology company. Working in a fast-paced dynamic environment brings the opportunity to make your own mark within the organization.

You will be rewarded a competitive remuneration package, the opportunity for personal development and to contribute to make a huge difference for patients.

About Kiadis

Kiadis Pharma’s allodepleted T-cell immunotherapy product can make haploidentical hematopoietic stem cell transplantations (HSCT) safer and more effective. Single dose Phase 2 data with lead product ATIR101™ given after a HSCT in patients with blood cancer shows a strong and clinically very relevant improvement over literature for the Baltimore protocol, without the risk of severe chronic Graft versus Host Disease (GVHD). Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101™ across the EU as an adjunctive treatment in HSCT for malignant disease. Kiadis Pharma received Day 120 questions in September 2017 and is on track for potential (conditional) approval in Q4 2018 and launch in H2 2019. Kiadis Pharma is conducting a Phase 3 trial with ATIR101™ across Europe and North America (head to head against the Baltimore protocol). The first patient was enrolled in December 2017. In September 2017, the US Food and Drug Administration (FDA) granted ATIR101™ the Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe.

About Kiadis Pharma


Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients. Kiadis Pharma believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT), thereby meeting a significant unmet medical need with its products.

More about Kiadis Pharma

Contact information

Kiadis Pharma
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

+31 (0)20 314 02 50
+31 (0)20 314 02 51
recruitment@kiadis.com